CAPR241018C30000
- 0.11
- -0.14-56.00%
Capricor Therapeutics Newsroom
Capricor Therapeutics Analyst Ratings
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40
Buy Rating Affirmed for Capricor Therapeutics Amid Promising Developments in DMD-cardiomyopathy Treatment
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Oppenheimer Keeps Their Buy Rating on Capricor Therapeutics (CAPR)
A Quick Look at Today's Ratings for Capricor Therapeutics(CAPR.US), With a Forecast Between $25 to $43
Capricor Therapeutics Is Maintained at Outperform by Oppenheimer
Buy Rating Affirmed for Capricor Therapeutics on Promising DMD-cardiomyopathy Treatment Prospects
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $15
Capricor Therapeutics Price Target Maintained With a $8.00/Share by Cantor Fitzgerald
Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $12
Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $12
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $15
Capricor Therapeutics Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Raises Target Price to $15
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40
Capricor Therapeutics Analyst Ratings
Buy Rating Affirmed for Capricor Therapeutics Amidst Expanded Partnership and Regulatory Advancements
Capricor Therapeutics' Strong Potential Justifies Buy Rating Amidst Strategic Progress and Positive Clinical Developments
Oppenheimer Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)